What We Know About Immunity

Prognosis: Misconception

Bloomberg

Health & Fitness, Science

4.1 • 838 Ratings

🗓️ 31 July 2020

⏱️ 13 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In the race to study immunity to the virus, scientists first focused on antibodies -- proteins that stick to and disable foreign invaders. That’s because creating antibodies is the basis for most successful vaccines, so scientists are interested in learning who develops coronavirus antibodies, how long they stick around, and how effective they are at keeping people from getting infected again. But recent studies show there may be another weapon inside the human body that can rouse fresh antibody soldiers long after the first have left the battlefield. Bloomberg senior editor Jason Gale explains that T cells may be part of the key to blunting the coronavirus contagion.

See omnystudio.com/listener for privacy information.

Transcript

Click on a timestamp to play from that location

0:00.0	What could you do if your data was working for you and not against you? With Bloomberg delivering
0:07.3	enterprise data directly to your systems, you get easy access to the details you want, optimized for
0:14.1	higher level analysis, and financial data experts committed to helping you maximize your every move.
0:25.8	Our data is made for more, so you can show the world what you're made of.
0:29.6	Visit Bloomberg.com slash enterprise data to learn more.
0:41.2	Welcome to Prognosis. I'm Laura Carlson. It's day 142 since coronavirus was declared a global pandemic.
0:49.8	Today's main story, scientists have been focused on studying virus antibodies to develop a vaccine.
0:59.2	But encouraging new research shows our bodies may be developing other weapons that could be key to slowing the outbreak.
1:04.9	But first, here's what happened in virus news today.
1:18.2	Vietnam confirmed its first death from the pandemic, after a sudden cluster of cases emerged in the coastal city of Danang.
1:23.5	For more than three months, the country appeared to have beaten back the virus.
1:30.2	The death of a 70-year-old man comes seven months after the nation recorded its first virus cases. The U.S. government pledged its biggest investment yet in a vaccine. The Trump
1:38.7	administration will provide as much as $2.1 billion in funding to vaccine partners Sanofi and Glaxo-SmithKline.
1:47.9	The funding will support clinical trials and manufacturing, while allowing the U.S. to secure
1:53.6	100 million doses of the shot, if it's successful.
1:58.5	The country has an option to receive an additional 500 million doses longer term.
2:05.7	The U.S. has made billions of dollars in commitments to other experimental vaccines,
2:11.6	stoking concerns that some countries will be left behind.
2:16.8	In England, more than 4 million people are being forced inside. Some countries will be left behind.
2:17.5	In England, more than 4 million people are being forced inside.
2:22.8	A large part of the country's northern region must comply with new, tighter lockdown rules.
2:29.5	Prime Minister Boris Johnson is rushing to tackle a new spike in cases, and his administration has forbidden
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Bloomberg, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Bloomberg and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.